Oliver Surriga

464 total citations
10 papers, 303 citations indexed

About

Oliver Surriga is a scholar working on Molecular Biology, Ophthalmology and Pathology and Forensic Medicine. According to data from OpenAlex, Oliver Surriga has authored 10 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Ophthalmology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Oliver Surriga's work include Ocular Oncology and Treatments (5 papers), Cancer Mechanisms and Therapy (2 papers) and Cancer-related Molecular Pathways (2 papers). Oliver Surriga is often cited by papers focused on Ocular Oncology and Treatments (5 papers), Cancer Mechanisms and Therapy (2 papers) and Cancer-related Molecular Pathways (2 papers). Oliver Surriga collaborates with scholars based in United States, Canada and United Kingdom. Oliver Surriga's co-authors include Gary K. Schwartz, Grazia Ambrosini, Ruimin Huang, Vinagolu K. Rajasekhar, Elisa de Stanchina, William D. Tap, Parag P. Patwardhan, Michael J. Beckman, Ronald P. DeMatteo and Richard D. Carvajal and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Oliver Surriga

10 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver Surriga United States	6	146	112	101	100	49	10	303
Elaine M. Binkley United States	11	143 1.0×	188 1.7×	141 1.4×	120 1.2×	29 0.6×	42	401
Jessica Sher United States	6	192 1.3×	190 1.7×	91 0.9×	89 0.9×	37 0.8×	8	333
María Gomez‐Caraballo United States	8	128 0.9×	123 1.1×	185 1.8×	34 0.3×	136 2.8×	15	392
Berber M. Mol Netherlands	8	128 0.9×	201 1.8×	197 2.0×	62 0.6×	11 0.2×	11	326
Simone Lubrano United States	6	182 1.2×	83 0.7×	61 0.6×	43 0.4×	19 0.4×	9	289
Edward Walczak United States	3	132 0.9×	152 1.4×	70 0.7×	68 0.7×	19 0.4×	7	239
Harutyun Melkonyan Germany	13	232 1.6×	97 0.9×	26 0.3×	133 1.3×	27 0.6×	20	363
María José Gamundi Spain	13	234 1.6×	92 0.8×	58 0.6×	12 0.1×	38 0.8×	19	365
Laura M. McKay United States	5	103 0.7×	10 0.1×	113 1.1×	31 0.3×	42 0.9×	6	249
Elina Pietilä Finland	10	175 1.2×	15 0.1×	143 1.4×	35 0.3×	36 0.7×	11	352

Countries citing papers authored by Oliver Surriga

Since Specialization

Citations

This map shows the geographic impact of Oliver Surriga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Surriga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Surriga more than expected).

Fields of papers citing papers by Oliver Surriga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Surriga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Surriga. The network helps show where Oliver Surriga may publish in the future.

Co-authorship network of co-authors of Oliver Surriga

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Surriga. A scholar is included among the top collaborators of Oliver Surriga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Surriga. Oliver Surriga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Bao, Riyue, Oliver Surriga, Daniel J. Olson, et al.. (2020). Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Research. 31(1). 27–37. 11 indexed citations

Khan, Shaheer, Jose Lutzky, Alexander N. Shoushtari, et al.. (2020). Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.. Journal of Clinical Oncology. 38(15_suppl). 10075–10075. 7 indexed citations

Schwartz, Gary G., et al.. (2019). Suppression of KRAS-G12D and BRAF-V600E oncogene transcription with PNA-conjugates. Annals of Oncology. 30. v1–v1. 4 indexed citations

Surriga, Oliver & Gary K. Schwartz. (2018). Abstract 2940: Chemosensitization of cholangiocarcinoma by guadecitabine. Cancer Research. 78(13_Supplement). 2940–2940. 1 indexed citations

Surriga, Oliver, et al.. (2017). Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth. Cancer Gene Therapy. 24(9). 401–408. 3 indexed citations

Patwardhan, Parag P., Oliver Surriga, Michael J. Beckman, et al.. (2014). Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs. Clinical Cancer Research. 20(12). 3146–3158. 94 indexed citations

Surriga, Oliver, et al.. (2013). Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model. Molecular Cancer Therapeutics. 12(12). 2817–2826. 87 indexed citations

Surriga, Oliver, et al.. (2013). Abstract 2706: Crizotinib, a selective c-Met inhibitor, prevents metastasis to the liver and lungs in a primary uveal melanoma mouse model.. Cancer Research. 73(8_Supplement). 2706–2706. 1 indexed citations

Ambrosini, Grazia, Christine A. Pratilas, Li-Xuan Qin, et al.. (2012). Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance. Clinical Cancer Research. 18(13). 3552–3561. 78 indexed citations

10.

Surriga, Oliver, et al.. (2009). Altered hepatic inflammatory response in the offspring following prenatal LPS exposure. Immunology Letters. 123(1). 88–95. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact